drugset / Trial / NCT01203254

Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease

NCT01203254

Phase 4 Terminated 34 enrolled Florian Beigel
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy of cholestagel to reduce the frequency of soft and liquid stools per day in patients with CD in clinical remission with symptoms of BAM and to assess the improvement in stool consistency and quality of life in these patients and to assess the safety of cholestagel.

Timeline

Start
2010-10
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Colesevelam Other / unclassified 1250 mg